Schellenberg Wittmer: Santhera sells its Raxone®/Idebenone business
Schellenberg Wittmer has provided legal counsel to Santhera Pharmaceuticals Holding in the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici. The deal marks a significant update to the existing license agreement signed between the two companies in 2019.
Under the acquisition agreement, Chiesi will take over all assets and certain liabilities associated with idebenone in all indications worldwide, including Raxone in LHON (Leber’s Hereditary Optic Neuropathy), for which Chiesi already possessed exclusive license rights globally since 2019, except in North America and France. As part of the consideration, Chiesi will also assume responsibility for the settlement agreed upon between Santhera and the French reimbursement authorities concerning Raxone in LHON, amounting to approximately EUR 25.3 million.
The team of Schellenberg Wittmer consisted of partners Pascal Hubli (corporate/m&a, pictured) and Philipp Groz (IP/life sciences) as well as senior associate Elia Schunck (corporate/m&a).
